{"id":"W4415749836","doi":"10.1200/oa-25-00099","title":"Alliance A022106: A Phase II/III Trial of Nab-Paclitaxel and Gemcitabine ± Cisplatin as Second-Line Treatment for <i>BRCA1/2</i> or <i>PALB2</i> Mutant Metastatic Pancreatic Ductal Adenocarcinoma (PLATINUM)","year":2025,"lang":"en","type":"article","venue":"JCO oncology advances.","topic":"Pancreatic and Hepatic Oncology Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Gemcitabine; Pancreatic ductal adenocarcinoma; Cisplatin; Mutant; Pancreatic cancer; Adenocarcinoma; Chemotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0009676346,0.0005865213,0.002860314,0.0002991398,0.0003676096,0.00001849053,0.0002465493,0.0003501784,0.0008075323],"category_scores_gemma":[0.001398732,0.0004329562,0.0003046229,0.0005789643,0.0009050164,0.0002649809,0.0001557722,0.0004233035,0.00001228955],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006156456,"about_ca_system_score_gemma":0.002426721,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00008702465,"about_ca_topic_score_gemma":0.0004341743,"domain_scores_codex":[0.9959649,0.0002808635,0.001540676,0.000939864,0.0003843429,0.000889319],"domain_scores_gemma":[0.9947833,0.0031806,0.0006254743,0.0006884336,0.0003525433,0.000369608],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.7620034,0.02356279,0.01690984,0.003379589,0.006558637,0.002517534,0.003388901,0.00002346577,0.03336572,0.005090642,0.005965413,0.1372341],"study_design_scores_gemma":[0.6812475,0.1509905,0.001702052,0.0007204623,0.006380732,0.001214207,0.002185266,0.003100382,0.01074635,0.005804527,0.1351315,0.0007764591],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9697164,0.01200619,0.001428973,0.00315583,0.0005176914,0.006230346,0.0002749622,0.00007606516,0.006593506],"genre_scores_gemma":[0.9295827,0.00521729,0.02687526,0.001576654,0.0004142717,0.002813041,0.0002353758,0.00007116425,0.03321424],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1364577,"threshold_uncertainty_score":0.9998122,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.05262911651944999,"score_gpt":0.4200712748728941,"score_spread":0.3674421583534441,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}